PD ‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

ConclusionGiven the relatively low incidence of immune ‐related AEs and the comparability of clinical outcomes, ICIs can be treatment option of NSCLC patients with special issues.

Source: Cancer Medicine - February 7, 2020 Category: Cancer & Oncology Authors: Seonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, Jong ‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn Tags: ORIGINAL RESEARCH Source Type: research